

# Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK

written by Raj Shah | February 26, 2024

*Exclusive rights to universal CAR technology platform designed to target multiple antigens simultaneously, recently expanded to include SNAP-CAR NK cells, has potential to impact various autoimmune diseases in addition to oncology indications.*

February 26, 2024 ([Source](#)) – Coeptis Therapeutics Holdings, Inc. (NASDAQ: [COEP](#)) (the “Company” or “Coeptis”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced that it has expanded its exclusive license agreement with the University of Pittsburgh to include autoimmune indications as part of its ongoing development of SNAP-CAR T and SNAP-CAR NK. This amended agreement builds upon the original exclusive license agreement with the University of Pittsburgh for SNAP-CAR T Cells, a “universal” CAR T technology platform designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, and a recent amendment to the agreement for SNAP-CAR NK, an allogeneic natural killer (NK) cell therapy platform.

Autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis, are known to result from autoreactive B cells. Recent research, including a paper just published in [The New England Journal of Medicine](#),

suggests that CD19-targeting chimeric antigen receptor (CAR) T cells, which have proven to be highly efficient in B cell malignancies, can also target autoreactive B cells that trigger autoimmune diseases.

[Research published in the peer-reviewed journal \*Nature Communications\*](#) demonstrated the ability of SNAP-CAR to provide a powerful adaptor strategy for fully programmable targeting of engineered cells to multiple antigens, including CD19. Based on these findings, Coeptis Therapeutics plans to expand the development of the SNAP-CAR platform to target the multibillion-dollar autoimmune disease market in addition to hematologic and solid tumors.

“We remain committed to developing these remarkable technologies as treatments for various indications across oncology where there is immense unmet need, however we also recognize the enormous potential for these platform technologies to address and possibly revolutionize the treatment landscape of autoimmune diseases,” said Dave Mehalick, President and CEO of Coeptis Therapeutics. “Our SNAP-CAR technologies have the potential to position us at the forefront of next-generation autoimmune directed therapies targeting multiple antigens through combinatorial use of different adaptors.”

“We are again excited to expand our license with Coeptis,” said Jason Lohmueller, Ph.D., Assistant Professor of Surgery and Immunology in the Division of Surgical Oncology Research, University of Pittsburgh. “Leveraging the universal SNAP-CAR technology, may bring multiple exciting and revolutionary treatments modalities to the clinic for diverse indications in oncology and autoimmune disease, benefiting patients and the entire healthcare industry.”

According [American Autoimmune Related Disease Association](#), there

are more than 100 autoimmune diseases impacting 1 in every 5 Americans, 75% of whom are women. These diseases are among the top 10 causes of death in America, causing great pain and suffering, with significant socioeconomic impact as well. Globally, the treatment market is forecasted to grow from \$7.68 billion in 2024 to \$12.64 in 2028, to according to [The Business Research Company](#).

### **About Coeptis Therapeutics Holdings, Inc.**

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively “Coeptis”), is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis’ product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis’ business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer and infectious diseases. The Company is headquartered in Wexford, PA. For more information on Coeptis visit <https://coeptistx.com/>.

### **Cautionary Note Regarding Forward-Looking Statements**

This press release and statements of our management made in

connection therewith contain or may contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company’s securities on the Nasdaq Capital Market; (2) the risk that the integration of the Deverra licensed assets will disrupt current plans and operations of the Company; (3) the inability to recognize the anticipated benefits of the newly-licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (4) the risks that the Company’s products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (5) costs related to integrating the newly-licensed Deverra assets and pursuing the contemplated asset development paths; (6) changes in applicable laws or regulations; (7) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (8) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and

uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at [www.sec.gov](http://www.sec.gov). We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.

## **CONTACTS**

### **Coeptis Therapeutics, Inc.**

Andy Galy, Sr. VP of Communications

504-416-6965

[andy.galy@coeptistx.com](mailto:andy.galy@coeptistx.com)

### **Tiberend Strategic Advisors, Inc.**

*Investors*

Daniel Kontoh-Boateng

862-213-1398

[dboateng@tiberend.com](mailto:dboateng@tiberend.com)

*Media*

David Schemelia

609-468-9325

[dschemelia@tiberend.com](mailto:dschemelia@tiberend.com)

SOURCE Coeptis Therapeutics, Inc.